Open AccessIs there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis?
Author(s) -
Sofia Fernanda Gonçalves Zorzella-Pezavento,
Luiza Ayumi Nishiyama Mimura,
Marina Bonifácio Denadai,
William Danilo Fernandes de Souza,
Thais Fernanda de Campos Fraga-Silva,
Alexandrina Sartori
Publication year - 2022
Publication title -
neural regeneration research/neural regeneration research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.93
H-Index - 38
eISSN - 1876-7958
pISSN - 1673-5374
DOI - 10.4103/1673-5374.335139
Subject(s) - multiple sclerosis , medicine , experimental autoimmune encephalomyelitis , vitamin d and neurology , disease , adverse effect , neuroprotection , autoimmune disease , therapeutic window , demyelinating disease , immunology , bioinformatics , pharmacology , biology
Multiple sclerosis is an autoimmune treatable but not curable disease. There are a multiplicity of medications for multiple sclerosis therapy, including a class entitled disease-modifying drugs that are mainly indicated to reduce the number and severity of disease relapses. Not all patients respond well to these therapies, and minor to severe adverse effects have been reported. Vitamin D, called sunshine vitamin, is being studied as a possible light at the end of the tunnel. In this review, we recapitulated the similar immunopathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis, the immunomodulatory and neuroprotective potential of vitamin D and the state-of-art concerning its supplementation to multiple sclerosis patients. Finally, based on our and other groups' experimental findings, we analyzed the need to consider the relevance of the route and the different time-point administration aspects for a more rational indication of this vitamin to multiple sclerosis patients.